Printer Friendly

KODAK TO MOVE FORWARD WITH ARBITRATION FOLLOWING COURT RULING IN KODAK/CETUS CASE

 KODAK TO MOVE FORWARD WITH ARBITRATION
 FOLLOWING COURT RULING IN KODAK/CETUS CASE
 ROCHESTER, N.Y., Dec. 4 /PRNewswire/ -- Eastman Kodak Company (NYSE: EK) today announced it will proceed with its plans to arbitrate rights to polymerase chain reaction (PCR) technology with Cetus Corporation.
 The announcement follows a decision by the Court of Chancery, New Castle County, Del., that denied Kodak's motion for a preliminary injunction, conditional upon Hoffman LaRoche's agreement by Dec. 6 to abide by the decision of the arbitrators.
 "We are gratified by the court's recognition that all the relevant parties need to be bound by the outcome of the arbitration," said Jose Coronas, vice-president and general manager of Kodak's Clinical Products Division.
 Kodak stands firm in its resolve to establish its rights to technology in the field of in vitro human diagnostics, including PCR technology," Coronas added. "Kodak intends to commercialize a family of diagnostic products based on PCR technology and we hope to announce our first new product within the next year.
 "We have invested tens of millions of dollars in the development of diagnostic tests utilizing this technology for a range of conditions and disease states, including genetic markers, oncology and infectious diseases," Coronas noted. "These products will be based on PCR technology for which Kodak has exclusive licenses under our contract with Cetus. The purpose of the arbitration is to resolve our rights prior to commercialization of these products."
 Kodak and Cetus entered into a contract in Feb. 1986 to jointly develop human diagnostic products, including nucleic acid diagnostic products based on PCR technology. Cetus terminated the development program in Feb. 1989, despite Kodak's desire to continue.
 "Kodak researchers have made substantial scientific and technical progress in further developing PCR technology since Cetus terminated our agreement, and we have filed for numerous patents in this area," CoronA. )'dde d.
 In 1988, Kodak introduced its SureCell line of rapid diagnostic test kits, developed with Cetus under this same joint development program. Included are tests for pregnancy, herpes, chlamydia and Strep-A, and Kodak is the exclusive marketer of these products.
 In 1990, Kodak expanded its clinical chemistry business into immunodiagnostics through the formation of a joint venture company, Amerlite Diagnostics Limited.
 -0- 12/4/91
 /CONTACT: Paul C. Allen of Eastman Kodak Company, 716-724-5802/
 (EK) CO: Eastman Kodak Company ST: New York IN: CHM SU:


LC -- CL012 -- 9315 12/04/91 15:18 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 4, 1991
Words:399
Previous Article:LG&E ENERGY CORP. BOARD OF DIRECTORS DECLARES QUARTERLY DIVIDEND
Next Article:/CORRECTION -- NERCO INC./
Topics:


Related Articles
TRIAD SUED ON BASIS OF RECENT SUPREME COURT KODAK RULING
U.S. SUPREME COURT ISSUES A SECOND MAJOR RULING IN FAVOR OF INDEPENDENT SERVICE ORGANIZATIONS
KODAK, HOFFMANN-LA ROCHE AND CHIRON
KODAK TO RECEIVE PATENT FOR PCR DEVICE FOR DNA DIAGNOSTICS IN HOSPITAL LABORATORIES
FUJI PHOTO FILM U.S.A., INC. RESPONDS TO KODAK'S MOST RECENT FILING ON SECTION 301 COMPLAINT WITH UNITED STATES TRADE REPRESENTATIVE
FUJIFILM FILES WITH USTR INITIAL COMMENTS ON KODAK'S RECENT SUBMISSION
FUJIFILM: NEW EVIDENCE PROVES KODAK IS WIDELY AVAILABLE IN JAPAN; DETAILED REPORT BY FUJIFILM EXPOSES KODAK'S 'DISTRIBUTION BOTTLENECK' MYTH
LEADING ANTITRUST EXPERTS SAY KODAK CLAIMS ABOUT JAPANESE MARKET COULD NOT SUCCEED UNDER U.S. ANTITRUST LAW
FUJIFILM DETAILS KODAK'S CONTRADICTIONS ON PRICES IN JAPAN; FUJIFILM'S USTR SUBMISSION CONFIRMS COMPETITIVE PRICING IN JAPAN
kelly's i: KODAK COURT ON CAMERA..

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters